Skip to main content

Table 4 Percent changes in cerebrospinal fluid amyloid precursor protein fragment levels and cerebrospinal fluid total tau/phosphorylated tau protein levels from baseline at day 28 across treatment groups

From: Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Safety analysis set

Caucasian

Japanese

Early AD

Preclinical AD

Percent change from baseline at day 28

Placebo

JNJ-54861911

Placebo

JNJ-54861911

10 mg

50 mg

10 mg

50 mg

CSF sAPPα (μg/ml), n

12

15

15

6

6

6

 Mean (SD)

− 2.60 (15.336)

88.74 (60.035)

114.28 (50.461)

11.96 (33.788)

61.37 (24.755)

82.49 (42.820)

 Median (range)

− 6.14 (− 27.1; 23.2)

69.32 (28.4; 264.2)

121.38 (11.4; 187.7)

2.03 (− 21.1; 66.8)

60.22 (33.7; 104.2)

86.71 (11.6; 136.2)

 95% CI of mean

(− 12.3; 7.1)

(55.5; 122.0)

(86.3; 142.2)

(− 23.50; 47.42)

(35.39; 87.35)

(37.55; 127.42)

 LS mean

113.02

218.19

249.66

11.04

62.60

82.17

 Difference of LS means (SE)

1.93 (1.100)

2.21 (1.101)

51.57 (21.480)

71.13 (20.649)

 95% CI

(1.59; 2.34)

(1.82; 2.68)

(5.49; 97.64)

(26.84; 115.41)

CSF sAPPβ (μg/ml), n

12

15

15

6

6

6

 Mean (SD)

− 2.05 (13.485)

− 64.34 (10.208)

− 90.70 (2.785)

12.40 (29.163)

− 66.90 (5.222)

− 91.30 (3.570)

 Median (range)

− 5.32 (− 21.7; 22.7)

− 67.25 (− 75.4; − 39.6)

− 90.40 (− 96.7; − 85.3)

3.29 (− 17.5; 59.5)

− 65.78 (− 76.1; −61.1)

− 91.21 (− 96.5; − 86.0)

 95% CI of mean

(− 10.6; 6.5)

(− 70.0; − 58.7)

(− 92.2; − 89.2)

(− 18.20; 43.01)

(− 72.38; − 61.42)

(− 95.05; − 87.55)

 LS mean

142.68

51.70

13.51

11.98

− 65.86

− 91.91

 Difference of LS means (SE)

0.36 (1.113)

0.09 (1.116)

− 77.84 (10.543)

− 103.88 (10.196)

 95% CI

(0.29; 0.45)

(0.08; 0.12)

 

(− 100.45; − 55.23)

(− 125.75; − 82.02)

CSF total sAPP (μg/ml), n

12

15

15

6

6

6

 Mean (SD)

− 7.80 (13.442)

− 13.34 (19.260)

− 15.29 (20.330)

0.06 (16.444)

− 1.55 (27.494)

− 24.85 (21.689)

 Median (range)

− 5.86 (− 34.4; 19.7)

− 13.34 (− 41.3; 19.6)

− 17.39 (− 44.7; 21.9)

1.73 (− 27.0; 22.8)

− 10.40 (− 23.3; 51.2)

− 16.94 (− 53.7; − 2.6)

 95% CI of mean

(− 16.3; 0.7)

(− 24.0; − 2.7)

(− 26.6; − 4.0)

(− 17.19; 17.32)

(− 30.40; 27.31)

(− 47.61; − 2.08)

 LS mean

734.76

701.82

679.71

0.49

− 2.16

− 24.65

 Difference of LS means (SE)

0.96 (1.087)

0.93 (1.086)

− 2.65 (14.338)

− 25.14 (13.383)

 95% CI

(0.81; 1.13)

(0.78; 1.09)

(− 33.40; 28.10)

(− 53.85; 3.56)

CSF total tau (ng/L), n

13

15

15

6

6

6

 Mean (SD)

− 1.68 (4.130)

4.18 (7.629)

8.02 (6.557)

− 17.00 (13.054)

− 4.67 (48.718)

− 38.83 (52.648)

 Median (range)

− 2.48 (− 9.8; 5.6)

6.76 (− 11.2; 16.1)

7.64 (− 4.5; 23.4)

− 20.50 (− 28.0; 7.0)

− 21.00 (− 38.0; 90.0)

− 32.50 (− 110.0; 250)

 95% CI of mean

(− 4.18; 0.81)

(− 0.04; 8.41)

(4.39; 11.65)

(− 30.70; − 3.30)

(− 55.79; 46.46)

(− 94.08; 16.42)

CSF P-tau (ng/L), n

12

15

14

6

6

6

 Mean (SD)

− 1.55 (4.252)

3.56 (4.797)

7.36 (3.648)

− 1.67 (2.422)

− 0.67 (5.046)

− 2.17 (6.911)

 Median (range)

0.00 (− 8.0; 5.4)

3.45 (− 4.6; 11.5)

7.42 (1.6; 16.7)

− 1.00 (− 5.0; 1.0)

− 2.00 (− 5.0; 9.0)

− 0.50 (− 11.0; 5.0)

 95% CI of mean

(− 4.26; 1.15)

(0.91; 6.22)

(5.25; 9.47)

(− 4.21; 0.88)

(− 5.96; 4.63)

(− 9.42; 5.09)

  1. Abbreviations: AD Alzheimer’s disease, Amyloid-beta, CSF Cerebrospinal fluid, LS Least squares, sAPP Soluble amyloid precursor protein